WHO issues guidelines on GLP-1 therapies for obesity treatment: Understanding the impact, safety considerations, and who can benefit

This week, the World Health Organization entered a new arena with its first global guideline on GLP-1 therapies for obesity treatment. Released on December 1, 2025, the document conditionally recommends drugs like semaglutide, liraglutide, and tirzepatide for adults with a BMI of 30 or higher-but only as part of a lifelong plan that pairs them with healthy diets, regular physical activity, and professional counseling. This comes at a time when over one billion people worldwide struggle with obesity a figure predicted to double by 2030-driving up deaths from heart disease, diabetes, and certain cancers while costing trillions in health expenses. WHO Director-General Dr. Tedros Adhanom Ghebreyesus called it a tool to treat obesity as the chronic disease it truly is-not a quick fix.

These drugs imitate glucagon-like peptide-1, a gut hormone that slows digestion, reduces appetite, and signals fullness to the brain. Clinical evidence shows they produce 15 to 25 percent weight loss over a year in many users, along with drops in blood sugar, heart risks, and kidney strain. In September 2025-the WHO already added them to its Essential Medicines List for high-risk type 2 diabetes cases, building momentum for broader obesity use. Trials confirm benefits extend beyond the scale, improving metabolic health and quality of life when people stick with them long-term.

GLP-1 receptor agonists mimic the natural hormone GLP-1-binding to its receptors to enhance glucose-dependent insulin secretion from pancreatic beta cells while suppressing glucagon release from alpha cells. They slow gastric emptying to reduce postprandial glucose spikes and act on hypothalamic neurons to promote satiety, curbing appetite and aiding weight loss. These mechanisms improve glycemic control in type 2 diabetes with low hypoglycemia risk, according to National Institute of Health.

WHO makes it clear that drugs work best with structured lifestyle changes. Low-certainty evidence points to better weight maintenance and health gains when patients follow intensive behavioral programs focused on balanced eating and movement. Picture platefuls of vegetables, lean proteins, whole grains, and fruits, cut back on processed sugars and-fats, alongside 150 minutes of weekly brisk walking, swimming, or strength training. Patients often report less hunger, making it easier to build these habits without feeling deprived. Without this combo, results fade, and weight rebounds.

The recommendations focus on non-pregnant adults with obesity, treating those at the highest risk of complications first. Physicians are to closely follow-up; counseling will be necessary to maintain results. There are many long-term safety data deficiencies on discontinuation and side effects, such as nausea or even muscle loss. Due to high costs and supply shortages-less than 10 percent of eligible people may have access to these drugs by 2030 without approaches such as pooled procurement or tiered pricing.

WHO calls on countries to reboot strategies with prevention policies, early screening, and equitable care systems. For health providers who will need training to integrate these therapies safely-and for governments tackling affordability to avoid widening rich-poor divides, regular check-ins when starting out track blood work, energy levels-and habits, adjusting as benefits emerge. This guideline marks a beacon of hope, combining science and real-world support to enable millions to manage a condition long stigmatized as mere willpower failure. True progress will require collective action so no one gets left behind in the fight for better health.